Lucence declares the opening of molecular diagnostics lab in Singapore
Category: #health  By Paroma Bhattacharya  Date: 2019-02-01
  • share
  • Twitter
  • Facebook
  • LinkedIn

Lucence declares the opening of molecular diagnostics lab in Singapore

Lucence Diagnostics has reportedly made it to the headlines for having announced the opening of its new headquarters & molecular diagnostics laboratory in Singapore. As per sources familiar with the matter, the new facility spanning 10,000 square feet will help the firm penetrate into newer regional markets and meet the rising demand for its clinical services, in addition to upscaling its R&D operations.

Incidentally, the company has already expanded its business operations across San Francisco & Hong Kong and now plans to tap the Singapore market.

Renowned for inventing blood tests for rapid as well as non-invasive cancer detection, Lucence’s blood tests are officially available in around right countries, inclusive of Singapore, India, Philippines, Hong Kong, Malaysia, Thailand, Myanmar, and Vietnam. According to a press release by Lucence Diagnostics, alongside the opening of its new molecular diagnostics facility, the company has also launched its flagship blood test LiquidHALLMARK®, capable of detecting around 50 genetic mutations, 2 viruses, and 14 types of cancers. The LiquidHALLMARK® is the first blood test of its kind that detects both cancer-causing viruses and genetic mutations with an astounding 99.9% accuracy and delivers an intensive molecular profile of the tumor with just a single blood draw using AmpliMARK™ - the firm’s proprietary amplicon-based sequencing technology.

Dr. Tan Min-Han, Founder & CEO, Lucence Diagnostics, was reportedly quoted stating that the expanded molecular diagnostics laboratory is the first step ahead for the company to fulfill its vision of attaining zero avoidable cancer deaths via early detection and enhanced treatment choices. Min-Han affirmed that the company is indeed thrilled to have played a pivotal role in bettering the lives of thousands of patients across Asia with its portfolio of blood tests for cancer screening and treatment selection.

The opening at Singapore incidentally, was officiated by Dr. Koh Poh Koon, Senior Minister of State, Ministry of Trade & Industry.



About Author

Paroma Bhattacharya

Email: [email protected]   

Paroma Bhattacharya

Paroma currently works as a content developer for Algosonline, MSF and a series of alike platforms. Fortified with a post-graduation degree in Journalism and Mass Communication, she delved head long into a writing career, creating resourceful and information enriched ...

Read More

More News By Paroma Bhattacharya

Outlook Therapeutics finishes patient registration for NORSE 1 trial
Outlook Therapeutics finishes patient registration for NORSE 1 trial
By Paroma Bhattacharya

  • NORSE 1 has registered a sum of 61 patients from nine different sites in Australia.
     
  • This study is first of the two current, well cont...

Lidl orders suppliers to pay duties on goods crossing Brexit borders
Lidl orders suppliers to pay duties on goods crossing Brexit borders
By Paroma Bhattacharya

  • The company has asked the British suppliers to pay any import tariffs levied on goods crossing borders after Brexit.
  • The current company contract c...

Bio-Thera Solutions commences Phase 1 study for Simponi® biosimilar
Bio-Thera Solutions commences Phase 1 study for Simponi® biosimilar
By Paroma Bhattacharya

Bio-Thera Solutions, a China based pharmaceutical company, has reportedly announced the start of dosing of its first batch of healthy volunteers in order to compare the safety and pharmacokinetics of BAT2506, proposed ...